Relation Between Protein 13 and Gestational Hypertensive Disorder

CompletedOBSERVATIONAL
Enrollment

138

Participants

Timeline

Start Date

March 12, 2020

Primary Completion Date

March 14, 2021

Study Completion Date

March 19, 2022

Conditions
Gestational Hypertension
Interventions
DIAGNOSTIC_TEST

Estimation of Protein 13

"Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000)~1. Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R\&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20).~2. Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21).~3. Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22)."

Trial Locations (1)

13511

Banha University, Banhā

All Listed Sponsors
lead

Benha University

OTHER

NCT05517512 - Relation Between Protein 13 and Gestational Hypertensive Disorder | Biotech Hunter | Biotech Hunter